Masuishi, T., Yamaguchi, K., Rodriguez, J. C. R., Corral de la Fuente, E., Kuboki, Y., Cremolini, C., … Siena, S. (2024). 73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101. In Annals of Oncology (Vol. 35, pp. S1432–S1432). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.10.095

Masuishi, T., K. Yamaguchi, JC Ruffinelli Rodriguez, E. Corral de la Fuente, Y. Kuboki, C. Cremolini, I Victoria Ruiz, et al. “73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101.” In Annals of Oncology, 35:S1432–S1432. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.10.095.

Masuishi T, Yamaguchi K, Rodriguez JCR, Corral de la Fuente E, Kuboki Y, Cremolini C, et al. 73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101. In: Annals of Oncology. Elsevier BV; 2024. p. S1432–S1432.

Masuishi, T., et al. “73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S1432–S1432. Crossref, doi:10.1016/j.annonc.2024.10.095.

Masuishi T, Yamaguchi K, Rodriguez JCR, Corral de la Fuente E, Kuboki Y, Cremolini C, Ruiz IV, Fernandez MEE, Strickler JH, Furqan M, Bashir B, Nduka C, Hippenmeyer J, Chan E, Xia C, Siena S. 73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101. Annals of Oncology. Elsevier BV; 2024. p. S1432–S1432.